Glipxen 5 MG (Tablet) (linagliptin INN)

Basic Product Information of Glipxen (Linagliptin) 5mg

How Glipxen (Linagliptin) Works

Glipxen contains Linagliptin, a selective inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme. DPP-4 rapidly breaks down incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), which the gut releases in response to meals to help regulate blood sugar.

By inhibiting DPP-4, Glipxen increases active incretin hormone levels, which in turn increases insulin release from the pancreas and decreases glucagon secretion, both in a glucose-dependent manner. This mechanism helps lower blood sugar after meals and between meals, while carrying a comparatively low intrinsic risk of hypoglycaemia when used alone.

Unlike most other DPP-4 inhibitors, Linagliptin is primarily eliminated through the bile and gut rather than the kidneys, meaning Glipxen can be used at the same 5mg dose without adjustment across all stages of renal impairment, including in patients on dialysis. Glipxen is a convenient once-daily oral tablet, taken with or without food.

Indications for Glipxen (Linagliptin)

Glipxen (Linagliptin) is indicated for the following:

Benefits of Glipxen (Linagliptin) 5mg

How to Take Glipxen (Linagliptin)

Monitoring and Dosage Adjustments

Regular monitoring is recommended during Glipxen treatment. Your healthcare provider will monitor blood glucose and HbA1c to assess treatment response, and watch for signs of hypoglycaemia, particularly if Glipxen is combined with a sulfonylurea or insulin. Monitoring also includes watchfulness for abdominal pain that could indicate pancreatitis, new or worsening skin blistering that could indicate bullous pemphigoid, and severe joint pain, which has been reported with this class of medication. Report any of these symptoms to your doctor promptly.

Drug Interactions and Important Information

Glipxen has a low overall drug interaction potential due to its minimal hepatic metabolism. However, it is a substrate of CYP3A4 and P-glycoprotein (P-gp); strong inducers of these pathways, such as rifampin, can meaningfully reduce Linagliptin levels and may reduce its glucose-lowering effect. Consider an alternative treatment if a strong P-gp or CYP3A4 inducer must be used long-term.

Combining Glipxen with a sulfonylurea or insulin increases the risk of hypoglycaemia; a lower dose of the sulfonylurea or insulin may be required. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Glipxen.

Side Effects and Precautions

Who Should Use Glipxen (Linagliptin)?

Glipxen is suitable for adults with Type 2 Diabetes Mellitus who need improved glycaemic control alongside diet and exercise, whether as monotherapy or added to metformin, a sulfonylurea, or insulin. It is particularly useful for patients with coexisting renal or hepatic impairment, where dose adjustment is not required. It is prescribed by general physicians, endocrinologists, and diabetologists. It is not suitable for Type 1 Diabetes or diabetic ketoacidosis.

Manufacturer

Glipxen (Linagliptin) is manufactured in Bangladesh under strict WHO-GMP, cGMP, and ISO-certified standards, offering an affordable and bioequivalent alternative to Trajenta by Boehringer Ingelheim/Eli Lilly at a fraction of the cost. [Please confirm the exact manufacturer name so it can be added here and in the specs table above.]

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of diabetes and chronic disease medications. We ensure Glipxen (Linagliptin) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Glipxen (Linagliptin) from Mediaid Pharmacy?

Glipxen represents a convenient, well-tolerated option for managing Type 2 Diabetes. As the generic equivalent of Trajenta by Boehringer Ingelheim/Eli Lilly, it delivers the same active ingredient, Linagliptin, with the same proven DPP-4 inhibition mechanism at a dramatically more affordable price. Manufactured under WHO-GMP and cGMP standards and distributed globally by Mediaid Pharmacy, Glipxen gives patients worldwide access to high-quality diabetes therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Linagliptin option with worldwide delivery, Glipxen from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Glipxen (Linagliptin)